Work

Three-Year Efficacy and Safety of Erenumab in Participants with Episodic Migraine and 2–4 Prior Preventive Treatment Failures: Results from the LIBERTY Study (P1-1.Virtual)

Year: 2022

Type: article

Source: Neurology

DOI: 10.1212/wnl.98.18_supplement.1100

Authors: Uwe Reuter, Peter Goadsby, Michel Ferrari, Gabriel Paiva da Silva Lima, Subhayan Mondal, Shihua Wen, Tracy Stites, Michal Arkuszewski, Michel Lanteri-Minet, Shaloo Pandhi

Institutions: Universitätsmedizin Greifswald, Charité – Universitätsmedizin Berlin, University of California, Los Angeles, King's College London, Wellcome Trust, Leiden University Medical Center, Amgen (United States), Novartis (Switzerland), Inserm, Université Côte d'Azur

Language: English

Topic: Migraine and Headache Studies

Subfield: Psychiatry and Mental health

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: closed

OpenAlex ID: W4389368800

FWCI:

Cites:

Cited by:

Related to: 10